|
|
|
RESEARCH PAPER
1 Department of Molecular Genetics and 2 Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA; 3 Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, Illinois 60607, USA; 4 Cleveland BioLabs, Inc., Cleveland, Ohio 44106, USA
Factors that mediate p53 tumor suppressor activity remain largely unknown. In this study we describe a systematic approach to identify downstream mediators of tumor suppressor function of p53, consisting of global gene expression profiling, focused short hairpin RNA (shRNA) library creation, and functional selection of genetic elements cooperating with oncogenic Ras in cell transformation. This approach is based on our finding that repression of gene expression is a major event, occurring in response to p53 inactivation during transformation and immortalization of primary cells. Functional analysis of the subset of genes universally down-regulated in the cells that lacked functional p53 revealed BTG2 as a major downstream effector of p53-dependent proliferation arrest of mouse and human fibroblasts transduced with oncogenic Ras. shRNA-mediated knockdown of BTG2 cooperates with oncogenic Ras to transform primary mouse fibroblasts containing wild-type transcriptionally active p53. Repression of BTG2 results in up-regulation of cyclins D1 and E1 and phosphorylation of Rb and, in cooperation with other oncogenic elements, induces neoplastic transformation of primary human fibroblasts. BTG2 expression was found to be significantly reduced in a large proportion of human kidney and breast carcinomas, suggesting that BTG2 is a tumor suppressor that links p53 and Rb pathways in human tumorigenesis.
[Keywords: BTG2; Rb; oncogenic Ras; p53; shRNA library; tumor suppressor gene]
Received September 6, 2005; revised version accepted November 28, 2005.
5 Corresponding author.
E-MAIL gudkov{at}ccf.org; FAX (216) 444-0512.
![]()
CiteULike
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
E.-S. Han, F. L. Muller, V. I. Perez, W. Qi, H. Liang, L. Xi, C. Fu, E. Doyle, M. Hickey, J. Cornell, et al. The in vivo gene expression signature of oxidative stress Physiol Genomics, June 10, 2008; 34(1): 112 - 126. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Toyota, H. Suzuki, Y. Sasaki, R. Maruyama, K. Imai, Y. Shinomura, and T. Tokino Epigenetic Silencing of MicroRNA-34b/c and B-Cell Translocation Gene 4 Is Associated with CpG Island Methylation in Colorectal Cancer Cancer Res., June 1, 2008; 68(11): 4123 - 4132. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kilbey, K. Blyth, S. Wotton, A. Terry, A. Jenkins, M. Bell, L. Hanlon, E. R. Cameron, and J. C. Neil Runx2 Disruption Promotes Immortalization and Confers Resistance to Oncogene-Induced Senescence in Primary Murine Fibroblasts Cancer Res., December 1, 2007; 67(23): 11263 - 11271. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Goulet, G. Gauvin, S. Boisvenue, and J. Cote Alternative Splicing Yields Protein Arginine Methyltransferase 1 Isoforms with Distinct Activity, Substrate Specificity, and Subcellular Localization J. Biol. Chem., November 9, 2007; 282(45): 33009 - 33021. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Xue, M. Haber, C. Flemming, G. M. Marshall, R. B. Lock, K. L. MacKenzie, K. V. Gurova, M. D. Norris, and A. V. Gudkov p53 Determines Multidrug Sensitivity of Childhood Neuroblastoma Cancer Res., November 1, 2007; 67(21): 10351 - 10360. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Slofstra, A. P. Groot, M. H. P. Obdeijn, P. H. Reitsma, H. ten Cate, and C. A. Spek Gene Expression Profiling Identifies C/EBP{delta} as a Candidate Regulator of Endotoxin-induced Disseminated Intravascular Coagulation Am. J. Respir. Crit. Care Med., September 15, 2007; 176(6): 602 - 609. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Farioli-Vecchioli, M. Tanori, L. Micheli, M. Mancuso, L. Leonardi, A. Saran, M. T. Ciotti, E. Ferretti, A. Gulino, S. Pazzaglia, et al. Inhibition of medulloblastoma tumorigenesis by the antiproliferative and pro-differentiative gene PC3 FASEB J, July 1, 2007; 21(9): 2215 - 2225. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Lefort, A. Mandinova, P. Ostano, V. Kolev, V. Calpini, I. Kolfschoten, V. Devgan, J. Lieb, W. Raffoul, D. Hohl, et al. Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCK{alpha} kinases Genes & Dev., March 1, 2007; 21(5): 562 - 577. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Donato, J. H. Suh, and N. Noy Suppression of Mammary Carcinoma Cell Growth by Retinoic Acid: the Cell Cycle Control Gene Btg2 Is a Direct Target for Retinoic Acid Receptor Signaling Cancer Res., January 15, 2007; 67(2): 609 - 615. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kawakubo, E. Brachtel, T. Hayashida, G. Yeo, J. Kish, A. Muzikansky, P. D. Walden, and S. Maheswaran Loss of B-cell translocation gene-2 in estrogen receptor-positive breast carcinoma is associated with tumor grade and overexpression of cyclin d1 protein. Cancer Res., July 15, 2006; 66(14): 7075 - 7082. [Abstract] [Full Text] [PDF] |
||||